Oncoviruses and Pathogenic MicroRNAs in Humans by Fujii, Yoichi Robertus
  The Open Virology Journal, 2009, 3, 37-51 37 
 
  1874-3579/09  2009 Bentham Open 
Open Access 
Oncoviruses and Pathogenic MicroRNAs in Humans 
Yoichi Robertus Fujii
* 
Retroviral Genetics Group, Nagoya City University, Nagoya, 467-8603, Japan 
Abstract: For disease prognosis, the functional significance of the oncoviral integration locus in oncogenesis has 
remained enigmatic. The locus encodes several transcripts without protein products, but microRNAs (miRNAs) have 
recently been identified from a common oncoviral integration locus. miRNA is an endogenous, non-coding small RNA by 
which gene expression is suppressed. Although miRNA genes, such as let-7 in the nematode, have orthologs among 
animals, the relationship between miRNAs and tumorigenesis or tumor suppression has been mainly discovered in several 
human cancers. On the contrary, this review clearly demonstrates the potential for human tumorigenesis of both miRNA 
genes from oncoviral integration sites and other cellular onco-microRNA genes, and we conclude that alteration of the 
miRNA profile of cells can be defined as tumorigenic or tumor suppressive. Thus, we explain here that virally-pathogenic 
miRNAs could also be partly responsible for oncogenesis or oncogene suppression to confirm’ the RNA wave’, with the 
miRNAs hypothesized as a mobile and functional genetic element. 
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INTRODUCTION 
  It is well known that multiple copies of oncogenes are 
expressed in cancer cells. Chromosomal translocation is a 
common oncogene amplification mechanism in hematologic 
cancer. For example, the Philadelphia (Ph) chromosome is 
activated by chromosomal translocation in chronic myeloid 
leukemia, and the oncogene abl implicated in Abelson 
mouse leukemia is activated by the chromosomal 
translocation T(9;22) [1]. Burkitt’s lymphoma is caused by 
Epstein-Barr virus (EBV), and the avian myelocytomatosis 
(myc) oncogene is activated by chromosomal translocation 
T(8;14) (q24;q32) into the immunoglobulin gene locus, such 
as IGH at 14q32, IGK at 2p12, or IGL at 22q11, which was 
seen in 75-85% of cancer individuals [2, 3]. The oncogene 
chimera products may cause tumors; however, oncogenic 
effects could also mediated by the human MYC proto-
oncogene [4, 5]. 
  Further, about 16% of multiple myeloma cases exhibit 
plasmacytoma variant translocation gene (PVT1) region 
rearrangement independent of immunoglobulin loci. PVT1 
and murine Pvt1 are common retroviral integration sites [2]. 
Murine leukemia virus (MLV) can integrate into the Pvt1 
locus and induce T lymphomas in mouse and rat. The 
provirus acts on the integration site by adding tags of its own 
sequences. There are two types of oncoviral integration. The 
first type occurs when the provirus inserts near the proto-
oncogene; the second type occurs when the provirus inserts 
into the oncogene itself. 
  The method of tagging a provirus without oncogenes has 
been used for identification of the cellular oncogene (c-onc) 
through its homology to the viral oncogene (v-onc). In this 
method, mice are infected with a retrovirus that excludes the  
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oncogene. Genes neighboring the proviral integration site 
can be identified and classified as either proto-oncogenes or 
tumor suppressor genes. Using this method, both protein-
coding genes and non-coding genes were discovered. 
Recently, microRNAs (miRNAs) from PVT1 have been 
identified as purported oncogenic miRNA (oncomirs) [6]. 
Further, using miRNA profiling of tumor cells and patient 
specimens, tumor suppressor miRNAs have also been 
identified. These discoveries regarding miRNA genes 
suggest that oncoviral integration should be reconsidered for 
tumorigenesis, and they highlight the importance of genome-
wide research including miRNA gene location on different 
chromosomes. The concept of investigating miRNA genes 
more closely might be also extended to analysis of 
quantitative trait loci (QTL) [7, 8]. 
  We recently introduced the RNA waves hypothesis 
(henceforth called RNA wave) that miRNA is a mobile and 
functional genetic element [9]. To confirm the resolution of 
RNA wave, this review first explains gene silencing pathway 
mediated by the miRNA gene, then uses oncogenic human 
herpesvirus 8 (HHV8) and retrotransposon I (including 
human immunodeficiency virus type 1 (HIV-1)) examples of 
the resident and genomic miRNA genes, respectively. Next, 
we focused on the relation between Knudson’s two-hit 
hypothesis on retinoblastoma (RB) as an early landmark [10] 
and RNA wave-based oncogenesis via oncoviruses. Finally, 
we discuss about the role of the miRNAs in tumorigenesis 
mechanisms and suggest the possibility of oncogenesis by 
viral miRNA inducing alteration of oncogenes or suppressor 
protein genes and oncogenic miRNA or suppressor miRNA 
gene expression. 
BIOGENESIS AND FUNCTION OF THE CRUCIAL 
SMALL RNAs 
  In early 1990s, the phenomenon of RNA silencing was 
observed in an experiment involving pigmentation of the 
Petunia flower [11-13]. The exogenous gene transfer 
suppressed expression of the endogenous cognate gene, 38    The Open Virology Journal, 2009, Volume 3  Yoichi Robertus Fujii 
suggesting co-suppression of homologous genes in plants 
caused at least in part by chromosomal methylation. Napoli 
et al. [14] reported that the transgene induced small double 
stranded RNAs (dsRNA) and pigmentation was observed in 
the cells/organism by expression of dsRNA. This 
phenomenon is termed as RNA interference (RNAi). 
  In 1998, Mello and Fire reported that exogenous dsRNA 
induced green fluorescent protein (GFP) or -galactosidase 
(-gal) gene silencing in gfp or -gal transgenic 
Caenorhabditis elegans [15]. When about 30 nucleotides 
(nts) of the complete paired dsRNA from gfp were 
transfected into nematode cells, the dsRNA bound Dicer-
dependently to RNA-induced silencing complex (RISC). 
Further, the longer dsRNA was transfected and then the 
dsRNA was digested by RNase Dicer and incorporated into 
RISC (Fig. 1a). 
  Short interfering RNAs (siRNAs) and Argonute (Ago) 
protein target messenger RNA (mRNA) to processing bodies 
(P-bodies) in the cytoplasm. These cytoplasmic bodies are 
the sites for mRNA degradation [16]. Human Ago1 and 
Ago2 are co-localized with the P-body-associated 
phosphorylated autoimmune antigenic protein, GW182 [17]. 
The N-terminus of GW182 was found to interact with the 
PIWI domain of Ago1 [18]. In addition, human Ago2 co-
localized with the decapping enzyme Dcp1a and Dcp2 for 
m
7G-capped, matured mRNA and the helicase Dhh1 (Fig. 
1a). Therefore, mRNA localization to P-bodies by siRNA is 
sufficient to cause translational repression with mRNA 
degradation by the exoribonuclease Xrn1 [16]. Later, 
endogenous siRNAs (19-30 nts) were cloned and it was 
shown in 2006 that, in the nematode, dominant function of 
endogenous RNA silencing is the transcriptional gene 
silencing (TGS) [19, 20]. Further, it has been reported that 
HIV-1 encodes viral siRNA precursor (Fig. 1b) [21]. 
  Protein coding genes comprise only 1.5-2% of the whole 
genome. According to Watson and Crick’s theory, known as 
the Central Dogma, a protein coding gene is transcribed from 
genome DNA to mRNA, then the mRNA is translated to 
produce a polypeptide chain. The genetic information in 
DNA is copied and transmitted to daughter cells via DNA 
replication. Upon primary transcription, the mRNA is 
synthesized by RNA polymerase II (Pol II). The primary 
transcripts are extensively modified in the nucleus after 
transcription. The modifications of the mRNA usually 
consist of three events. The first is cap formation of 5’-
terminus of the mRNA. The second is addition of a poly(A) 
tail at the 3’-terminus of the mRNA. The third is the removal 
of introns and the cap, and poly(A) tailing and the exons are 
produced during matured mRNA processing. 
  A secondary result of the Central Dogma theory was the 
concept that all necessary genetic information in contained 
within the protein-coding region. Therefore, genetic content 
in the non-coding region, except for introns and promoters, 
has been excluded from molecular biology studies. miRNAs 
can be generated from the non-coding region and can target 
to the 3’ untranslated region (UTR) of the mRNA. Further, 
miRNA is sometimes expressed from the intron. Therefore, 
splicing can be targeted by the intronic miRNA [22]. Thus, 
the Central Dogma is controlled by the miRNA genes   
because nearly 100% of coding transcripts are under the 
control of miRNAs and other short RNAs [23, 24]. While the 
host cell system following the Central Dogma is always used 
for viral protein synthesis, master regulator miRNA should 
control virus proliferation and pathogenesis [25, 26]. 
Although unknown protein coding genes as the open reading 
frames (orf) have only recently been established in 
computing analysis, it is now tenaciously understood that 
oncovirus has hidden miRNAs in their viral genome [27-32]. 
Computational analysis, northern blotting, and functional 
bio-analysis have showed the presence of HIV-1 miRNAs 
[33-35]. 
  The miRNA genes are expressed as the master regulator 
of the Central Dogma in plants, worms, flies, mammals, and 
viruses, and they play an important role in developmental 
timing [36], morphologic changes [37], cell proliferation and 
death [38], hematopoiesis [39], nervous system control [40], 
pancreatic insulin secretion [41], adipogenesis [42], 
oncogenesis [43, 44] and viral disease [45-48]. Although 
small RNAs originate from many sources, including cellular 
genomes, viral replication intermediates, aberrant cellular 
RNAs, overexpressed transgenes, and transposons, more 
than 500 miRNA genes from human genome nearly have 
been listed up in miRBase. The miRNA genes are 
transcribed by Pol II as primary transcripts (pri-miRNA) 
from human as well as viral genomes [49] (see the left panel 
in Fig. 1a). Most miRNAs are likely to be transcribed by Pol 
II as the class II gene [50]. The primary transcripts of 
miRNA have experimentally been reported to contain a cap 
structure and poly (A) tail [51]. In the reverse genetic 
method, RNA polymerase III (Pol III)-expressing siRNA can 
induce cell toxicity, but Pol II-expressing miRNA cannot 
[52]. Therefore, the Pol II transcript from hairpin-structured 
pri-miRNA might be more relevant than Pol III for class III 
genes. 
  Although some pri-miRNA from intron (mirtron) does not 
contain a 5’-cap or a poly (A) tail [49], expression of miRNAs 
is commonly regulated by a promoter and an enhancer [53, 
54]. In computational predictions with the CoVote method, 
most miRNAs have the same type of promoters as protein 
coding genes of C. elegans, H. sapiens, A thaliana and O. 
sativa [55]. Further, the K-Factor algorithm showed that the 
nucleotide composition of the miRNA upstream sequences is 
GC-rich (90%) [56]. However, the observation of expression 
of tens of thousands of non-coding RNAs (ncRNAs) suggests 
that the classical promoter-transcription-protein view may be 
incomplete because most of the ncRNAs identified have not 
been studied and the functions have not yet been investigated 
in genomic studies. 
  The pri-miRNAs are processed by RNase type III Drosha 
[57] and its cofactor DiGeorge syndrome critical region 8 
(DGCR8) to pre-miRNA ~50-100 nts long [58]. The pre-
miRNA is transported by exportin 5 (EXP5) from the 
nucleus to the cytoplasm [59, 60]. The exported pre-miRNAs 
are processed again by RNase type III Dicer and the trans-
activator RNA-binding protein (TRBP) [61] and/or protein 
activator of protein kinase activated by dsRNA (PACT) [62]. 
The diced and matured miRNA duplex (~19-25 nts) is 
incorporated into the miRNA-induced silencing complex 
(miRISC) [63]. One strand of the duplex, miRNA*, and the 
other strand, including matured miRNA, are guided to the 
target mRNA [64]. In some cases, miRNA* is degraded 
during this step. Prototype Onco-miRNA Integration  The Open Virology Journal, 2009, Volume 3    39 
 
 
Fig. (1). Human miRNA biogenesis and its sources. (a) Human miRNA genes are hidden in the protein non-coding regions and pri-miRNA 
involves from a long transcript precursor, which can be generated by Pol II or Pol III RNA promoters. The intronic miRNAs are transcribed 
by the Pol II promoters of the protein-coding genes. In the nucleus, the pri-miRNA is excised by Drosha RNase and the processed pre-
miRNA is transported by Expotin-5 to the cytoplasm of the cell. The pre-miRNA is diced by Dicer RNase and then miRNAs are 
incorporated into a RNA-induced silencing complex. The matured miRNA suppresses translation and transcription by uncertain mechanisms. 
On the other hand, nematode siRNA can be transfected into the cells, where either strand of the siRNA can bind to the RISC independently 
of Dicer. In the case of complementarily-paired miRNA and siRNA-to-mRNA sequences, both small RNAs induce mRNA degradation in 
the P-body. Human Ago1 and Ago2 are localized in the P-body and associated with GW182. The N-terminal GW182 protein can interact 
with the PIWI domain of Ago1. Ago2 also localizes with the decapping enzyme Dcp1 for matured mRNA and the helicase Dhh1. mRNA 
degradation by siRNA can be performed by the exoribonuclease Xrn1. But usually miRNA is uncomplementarily paired to the 3’ UTR of 
target mRNA; therefore, miRNA is believed not to destroy mRNA. (b) A schematic representation of three miRNA sources in relation to the 
human genome. Twelve, 9 and 43 miRNAs in the KSHV (DNA virus), HIV-1 (RNA virus) genome, and human 14q32 chromosome, 
respectively, are represented by the gray arrows. Protein coding regions are represented as the gray bars. Ten miRNAs (1-9 and 11) of KSHV 
reside in the non-coding region and two (K12-10 and 12) are within the kaposin gene. Two miRNAs (MIRH1 and MIRN367) of HIV-1 were 
cloned and expression was detected by northern blotting. Two (TAR-3p and 5p) were observed with the artificial bio-assay and are involved 
in the secondary structured TAR region. Five (#1-#5) were predicted by the computing analysis. The sequences of miR-#4 is partially 
overlapped into those of miR-N367. Two viral siRNAs (vs iRNA#1 and #2) were detected by computation and northern blotting. The type I 
retrotransposon RTL1 is involved in the imprinted chromosome region. Five miRNAs (miR-127, miR-136, miR-431, -432, and -433) in the 
RTL1 gene were isolated. The antisense RTL1 transcript is maternally expressed, and it was initially reported in an ovine model as anti-
PEG11. The maternal expression of the antisense transcript suggests to be controlled by these miRNAs. 
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  The miRNA generally have 5’-terminal monophosphates 
and a 2’, 3’ cis-diol at their 3’-terminus. Some 3’ 
modifications of miRNA have been reported [65, 66]. The 
two strands of miRNA from an incomplete paired dsRNA; 
therefore the numbers of miRNAs and their targets could be 
much greater than currently known. 
  The catalytic component of the RISC is the Ago protein, 
which has two domains of PIWI and the 
Piwi/Argonaute/Zwille (PAZ) for binding the guide strands 
[67, 68]. The PIWI and the 3’ UTR of the target mRNA were 
recognized by the bases 2-7 or 8 of the seed in the 5’ end of 
the miRNA as a guide. In the case of perfect complementary 
sequences, the target mRNA is sometimes degraded. The 
mechanisms are similar to those of exogenous siRNA (Fig. 
1a). In the case of perfect sequence complementarity, 
translation of the target mRNA is blocked in the P body by 
the RNAi machinery [69]. 
  Further, miRNA is sometimes associated with the RNA-
induced transcriptional complex (RITS), which induces 
heterochromatin assembly and inhibits transcription of the 
target gene [70, 71]. It has been reported that miR-29b 
localizes in the nucleus and the hexanucleotide element 
directs the process of nuclear import [72]. This strongly 
suggests that miRNAs could play a role in the regulation of 
transcription. Although the exact mechanism of histone 
modification by small RNAs is unclear, mutations in Dicer, 
Ago and RNA-directed RNA polymerase (RdRP) result in 
defects of heterochromatin assembly in S. pombe [73]. RITS 
contains small RNA, a chromodomain protein (Chp), Ago 
and some unknown proteins. RITS also recruits the RdRP 
complex (RDRC) and Swi6 heterochromatin protein 1 
(HP1)-family protein. Together with RTIS and RDRC, small 
RNAs facilitate heterochromatin modification targeting such 
as methylation of the lysine residue at position 9 of histone 
H3 (H3K9). Thus, miRNA targets not only the 3’ UTR, but 
also many other genes, and it is consequently speculated that 
miRNA could modulate almost all multi-gene expression 
[24]. In particular, miRNA could regulate several thousand 
genes, many more than the several hundred suggested in 
previous reports [74-76]. 
  Although miRNA-mediated gene silencing mechanisms 
have been implicated in inhibition of translation, protein 
degradation, capping prevention, inhibition of ribosomal set-
up, inhibition of mRNA circularization and deadenylation 
plus decapping in post-initiation process [77, 78], as well as 
the above-mentioned mRNA processing by intronic miRNAs 
[79, 80], the effects of RITS interacting with miRNA also 
remain to be elucidated (Fig. 1a). 
INVOLVEMENT OF VIRAL MIRNA GENES IN 
ONCOGENESIS 
  Kaposi’s sarcoma (KS) is a neoplasm with protean 
manifestations, so called opportunistic neoplasm as first 
described by Moritz Kaposi. This form of KS is designated 
as classic KS [81]. In early 1980s, KS was found to be one 
of the manifestations of human immunodeficiency virus type 
1 (HIV-1), which causes human acquired immunodeficiency 
syndrome (AIDS), and this form is designated as epidemic 
KS [82]. Although HIV infection may be endemic in New 
York and California, where epidemic KS is also prevalent,  
epidemic KS is not caused by HIV-1. In 1994, the DNA 
sequence of a novel herpesvirus was identified in AIDS-
associated KS [83]. The virus has been classified as a new 
human herpesvirus, HHV8 or Kaposi sarcoma-associated 
herpesvirus (KSHV). 
  Four KSHV proteins are produced in infected cells, and 
the proteins - kaposin, v-FLIP, v-Cyclin and the latency-
associated nuclear antigen (LANA) - may be critical to 
KSHV pathogenesis [84]. Although the proteins’ functions 
have been investigated, the mechanism of oncogenesis is still 
not clear. miRNAs have also been identified within KSHV 
and a cluster of 12 miRNAs were found to be encoded in the 
KSHV latency-associated region (Fig. 1b) [85]. The KSHV 
miRNA cluster down-regulated SPP1,  THBS1,  S100A2, 
PRG1,  ITM2A and RAB27A gene expression of HEK 293 
cells [86]. S100A2 interacts with the p53 family proteins p67 
and p73, and S100A2 can activate p53. Further, PRG1 is a 
granule proteoglycan secreted by hematopoietic cells, and it 
is involved in apoptosis. Samols et al. did not discuss the 
relationship between KS and S100A2 or PRG1, but their 
observations may be related with KS tumorigenesis. 
  According to computational and experimental analysis, 
HIV-1 encodes nine miRNAs (Fig. 1b) [34, 87-89]. HIV-1 
infection is associated with many cancers, including the 
above-mentioned KS; primary central nervous system 
lymphoma (PCNSL); non-Hodgkin’s lymphoma (NHL); and 
carcinoma of the uterine cervix, oral, anus and testis. 
Although approximately 50% of PCNSL is related to EBV 
[90, 91], it is also known that HIV-1 directly stimulates B 
lymphocytes causing polyclonal hyperglobulinaemia in 
serum and follicular hyperplasia in lymphoid tissues. Overall 
50% of outcomes remain poor understanding with PCNSL 
[92]. 
  The HIV-1 miRNA gene (hiv1-miR-H1) is located in U3 
region of the 3’-long terminal repeat (LTR) (Fig. 1b) and it 
down-regulates cellular apoptosis antagonizing transcription 
factor (AATF) gene expression. The AATF (or Che-1) 
interacts with Pol II and tumor suppressor retinoblastoma 
protein (RB) [93]. The AATF is also associated with an 
endogenous antagonist of prostate apoptosis-4 (Par-4). The 
Par-4 is reported to be involved in suppression of Bcl2 gene 
transcription [94]. Therefore, hiv1-miR-H1 (MIRH1) is 
likely to activate E2F activity and inhibit apoptosis. This 
may be a co-factor in the tumorigenesis of HIV-1 infection. 
SOMATIC MUTATION OF THE RESIDENT miRNA 
  Human carcinogenesis is caused by the somatic 
mutations. These mutations may be induced by 
environmental agents, such as ionizing radiation (1.5-2.0 Gy) 
and/or occur spontaneously. Environmentally-induced 
mutation occurs as a break in single-stranded DNA, leading 
to damaged dsDNA, which plays a major role in 
carcinogenesis, according to the two-hit kinetics hypothesis 
(Fig. 2a) [95]. Expanding the hypothesis of two-hit kinetics 
to the level of chromosomal mutation in loss of a tumor 
suppressor gene, the first hit is heterozygotic mutation and 
the second hit is homozygotic one. 
 The  RB gene has been reported to be associated with 
chromosomal changes at 13q14 in homozygotic mutation 
[96]. Recently, in mouse models, ultraviolet B irradiation 
(50J) was reported to change the profile of miRNA in mouse  
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Fig. (2). Incorporation of tumorigenesis and metastasis into the RNA wave. (a) Knudson’s two-hit hypothesis and the RNA wave. Sporadic 
retinoblastoma requires two hits of somatic mutation in homozygote gene by environmental factors [10]. The mutation of RNA is less stable 
than DNA and RNA has no repair enzymes. Environmental factors including viral miRNA or integrated proto-oncovirus miRNA can 
qualitatively and quantitatively change the profiles of resident miRNAs of cells. Deleted or ectopic miRNA alterations (called mutations) 
initiate tumorigenesis. In this case, the first hit to the resident miRNA genes, and the second hit to the genomic miRNA genes. A more 
sophisticated Knudson hypothesis may involve into more advanced RNA wave. (b) In the seed and soil hypothesis of metastasis, the primary 
tumor cells disseminate by intravasation to the blood or lymphatic system. This process requires an epithelial-mesenchymal transition (EMT) 
by the primary tumor cells, as well as primary tumors extravasation to distant tissues. There a mesenchymal-epithelial transition (MET) 
enables the primary tumors to change into the secondary tumors (metastasis). On the other hand, miRNAs such as miR-21 expressed in 
breast and ovarian cancer can easily be transported into the blood and possibly the lymphatic system. The cells in metastasis sites or their 
environment can alter profiles of miRNA expression by incorporation of the new miRNA into the cells. The change in the resident miRNAs 
may induce a change in the genomic miRNA and tumorigenesis via epigenetic chromatin modeling or chromosome mutation under the RNA 
wave. In this case, transfer of primary tumor cells with subsequent EMT and MET is not required at all. 
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Fig. (3). Master regulator miRNA of oncogenic and tumor suppressor. (a) The tumor suppressor has two pathways, RB and p53 pathway. 
The miR-16 family regulates the cell cycle G1/S by modulating CDK4/6-Cyclin D1/D2/D3 and CDK2-Cyclin E1/E2 complexes. Two 
complexes are related to RB phosphorylation, and the phosphorylated RB is released from E2F. Thus the activated E2F drives infinitive 
transcription from G1 into S. Another player in carcinogenesis is CDKN2A, which encodes p16
INK4A and p14
ARF. The former is transcribed 
from exons 1, 2 and 3, and the latter is from exon 1, 2 and 3 with different reading frames of the CDKN2A gene. p16 inhibits the CDK4/6-
Cyclin D complex and p14 mediates G1 arrest by destabilizing the MDM2 protein. The MDM2 oncogene induces many sarcomas by binding 
to p53 (TP53). Therefore, p14 maintains the level of p53. p53 phosphorylated by ATM inhibits CDK2/Cyclin E complex via p21
WAP/CIP 
activation with p27
KIP. The main mechanism of tumor suppression is intervention by CDK4/6-Cyclin D and CDK2-Cyclin E. miR-16 can 
induce apoptosis by suppression of Bcl2. Thus, the miR-16 family plays an important role for tumor suppression. Although viral 
oncoproteins, such as adenovirus E1A, SV40 T antigen, as well as human papillomavirus E7, bind RB, the HIV-1 viral MIRH-1 was recently 
shown to suppress AATF which inhibits E2F activation by association with RB. Therefore, oncoviral MIRH1 may be tumorigenic. (b) Cell 
cycle transcription by E2F is also modulated by a c-myc-regulated miRNA cluster miR-17-92 [138]. In the upper part of the figure showing 
the miR-17-92 cluster, the large box represents the pre-miRNA and the small box shows the mature miRNA. MYC (c-myc) promotes the 
transcription of both miR-17-92 and E2F by binding at the cacgtg site on the miR-17-92 gene and the E2F promoter. miR-17-5p and miR-
20a downregulate E2F gene expression. miR-17-92 results in the inhibition of apoptosis via the p14
ARF pathway. miR-155 oncogenic miRNA 
in oncoviral integration site BIC activates c-myc and inhibits p53 by inactivation of TP53INP1. In some cases, oncoviral integration 
upregulates miR-155 expression, but in other cases, oncoviral integration inhibits miR-17-92 expression. Thus, oncoviral integration is 
tumorigenic. However, no relation between integration site and miRNA genes has been reported. The primary cause of altered miRNA 
expression in cancer cells is still unaccounted for. While miR-125b-1 insertion into IGH locus has been found in acute lymphoblastic 
leukemia, if the oncovirus takes the resident miRNA as the MGE, the mobile miRNA may be able to alter the profiles of miRNA in infected 
cells. Subsequently, hidden oncoviral miRNAs may have an important role for tumorigenesis in the cells. 
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Table 1.  Oncomir and Tumor Suppressor miRNA Profiles in Human Cancers 
 
Human   miRNA  Involvement     
Cancer     Oncomir     Suppressor miRNA  Oncogene Target  References 
Oncoviral integration-induced      
Lymphoma
a) mir-1204        [166] 
   ( PVT-1)        
Erythroleukemia
a) miR-17-92        [165] 
   ( Fli-3)        
T-cell leukemia  miR-106a      c-myc  [164] 
   ( Kis2)        
   miR-19b-2         
   miR-92-2         
   miR-20b         
B-cell leukemia  miR-155    miR-17-92    [44] 
   ( BIC)       [142] 
Non-oncoviral          
Brain cancer  miR-21    miR-181    [169] 
   miR-221        [135] 
Breast cancer      miR-125b    [134] 
       miR-145     
       miR-21     
       miR-155     
Chronic      miR-15  BCL2  [120,  170] 
lymphocytic     miR-16    [119] 
leukemia           
Gastric cancer  miR-34b    miR-128b    [171] 
   miR-34c    miR-129     
   miR-128c    miR-148     
   miR-106b        [172] 
   miR-222         
Colorectal       miR-143  v-Ki-ras  (KRAS)  [43] 
neoplasia       miR-145    [173] 
Pancreatic cancer  miR-21    miR-375    [174] 
   miR-221         
   miR-222         
    miR-181a, b, d       
   miR-155        [145] 
Hepatocellular miR-18    miR-199    [175] 
carcinoma   miR-224    miR-195     
       miR-200     
       miR-125     
       miR-101 v-fos  [176] 
Lung cancer  miR-17-92    let-7  Ras  [136] 
   let-7a        [137] 
           [177] 
           [138] 
Papillary   miR-222       [130] 
thyroid   miR-146        [178] 
carcinoma   miR-181         
Teasticular miR-372        [179] 
germ cell    miR-373         
tumor            
Ovarian cancer  miR-21        [116] 
   miR-141         
    miR-200a, b, c       
   miR-203         
   miR-205         
      (In sera specimens)       
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NIH3T3 cells; miR-365 and oncogenic miR-21 were also 
upregulated [97]. Further, the radiation exposure resulted in 
significant alteration of miRNA expression in spleen and 
thymus tissues, and tumor suppressor miR-34a was 
increased, paralleled by a decrease in the expression of its 
target c-myc gene [98]. In human fibroblast cells, exposure 
of radiation (0.1-2.0 Gy) caused downregulation of miR-92b, 
a tumor suppressor (Table 1) [99]. These data suggest that 
miRNAs may act as specific regulators of cellular responses 
to environmental exposures, even if lower radiation doses 
than the level required to break of dsDNA, and miRNAs can 
contribute to cell tumorigenesis and/or repair (Fig. 2a). 
  In addition, it is well known that RNA does not have 
repair mechanisms, therefore the resident miRNA is more 
susceptible to environmental stimulation than genomic 
DNA. The two-hit theory is involved in the RNA wave. 
Without dsDNA damage, the X-ray-susceptible resident 
miRNA genes that are somatically mutated and/or the 
quantitatively changed miRNA profiles (the first hit) can be 
integrated into the DNA genome via transposing RNA, like 
the exosomal miRNAs [100] and then the altered genomic 
miRNA gene expression (the second hit) affects the 
phenotypic alteration of cells. It has been shown that the 
miR-125b-1 gene is inserted into IGH allele in B-cell acute 
lymhpoblastic leukemia by unknown mechanisms [101]. 
This process, rather than integration itself, may 
epigenetically introduce to a defect into a chromosome 
[102]. 
  Metastasis, the spread and growth of a primary tumour, is 
the most common cause of death for cancer patients. The 
primary tumor cells intravasate into the blood stream or 
lymphatic system and invade into new organ [103]. Then the 
secondary tumor (the seed) must be able to grow in the 
microenvirnment (the soil) of the secondary site. This is the 
seed and soil hypothesis. In this hypothesis, tumor cells 
switch their phenotype from epithelial-mesenchymal 
transition (EMT) to mesenchymal-epithelial transition 
(MET) (Fig. 2b) [104]. 
  Matastasis-related miRNAs has been reported. For 
example, miR-21 oncogenic miRNA is upregulated in 
metastasis of hepatocellular carcinoma, B cell lymphoma, 
cholangiocyte, and glioblastoma, as well as breast, 
colorectal, gastric, lung, ovarian, uterine, cervical, prostate, 
oesophageal, and pancreatic cancers [105]. miR-21 
suppresses  PDCD4,  MASPIN,  PTEN,  TPM1 and TIMP3 
metastasis suppressors [106-110]. The importance of other 
miRNAs, including miR-10b (upregulated), miR-126 
(downregulated) and miR-206 (downregulated) have also 
been demonstrated, and HOXD10 or SOX4 transcription 
factors are regulated by these miRNAs [111-115]. HOXD10 
or SOX4 expression decreases cancer malignancy by 
inhibition of tumor cell migration and ECM remodeling. 
Recently, the metastatic and oncogenic miR-21 gene was 
observed in serum specimens of ovarian cancer [116]. 
  In general, miRNA levels are similar among healthy 
individuals [117]. This finding supports the RNA wave that 
miRNA genes have mobile genetic element (MGE)-like 
mobility. Therefore, without transformation a primer tumor 
cell from EMT to MET, miRNA information can be sent to 
oncogenic-susceptible cells in the secondary site via  the 
blood stream (Fig. 2b). Thus, new opportunities for 
metastasis may arise from a circulating wave of oncogenic 
miRNAs in body fluid. 
ONCOGENIC AND TUMOR SUPPRESSOR miRNAs: 
CELL CYCLE ARREST INDUCED BY miRNAs 
  Proper regulation of the cell cycle is critical to regulation 
of cell growth and the prevention of cancer. Some miRNAs 
play an important role in initiation and progression of human 
cancer (Table 1). has-miR-15a and miR-16-1 are located at 
human chromosome 13q14, and deletion of this region 
causes B-cell chronic lymphocytic leukemia (CLL). An 
approximately 30 kb region of 13q14 contains both genes 
and approximate 68% CLL cases are the deleted mutation of 
this region [118]. 
  Further, expression of miR-15a and miR-16-1 has been 
reported to be related to Bcl2 expression in CLL and to 
down-regulate  bcl2 gene expression [119]. As a result of 
Bcl2 suppression, both genes induced apoptosis in tumor 
cells. Therefore, the miR-16 cluster inhibited the growth of 
CLL engrafts in nude mouse [120]. The miR-16 family 
negatively regulates cellular growth and the cell cycle to 
trigger G0/G1 accumulation via  Cyclin D1 (CCND1) 
suppression [121, 122]. 
  Retinoblastoma is one of genetic diseases, and 
approximately 40% of cases are familiar (MIM 180200) 
[10]. The two-hit hypothesis can be applied to RB. The RB 
gene as well as TP53 suppress tumor growth and is related to 
the cell cycle. RB is activated by dephosphorylation, and 
binds to cellular transcriptional factor E2F, and then cell 
cycle is stopped in G1/S check-point. CCND1 is cooperated 
to Cyclin kinase 4/6 (CDK4/6) complex and recruit RB 
[123-125]. While inactivation of RB is induced by 
phosphorylation of RB (Fig. 3a), deletion of miR-15 and 
miR-16 causes RB hyperphosphorylation and desregulation 
of cell growth. This suggests that miR-15 and miR-16 are 
regulators of the RB/E2F pathway. Therefore, miR-15a and 
miR-16-1 are tumor suppressors. 
  E2F1, E2F2 and E2F3 are all activators of cell cycle 
progression [126-129]. During G1, none of E2F is associated 
with RB. Therefore, either inactivation of RB or E2F1 
expression can promote apoptosis. The miR-17a and miR-20 
genes inhibited the translation of the E2F1 mRNA. Further, 
the miR-17-92 cluster is regulated by MYC protein in human 
B-cell lymphoma [130]. These results suggest that miR-17a 
and miR-20 can act as tumor suppressive miRNA [131]. 
  E2F1-3 expression was blocked by miR-20a via targeting 
of E2F1-3 mRNA at the 3’ UTR, and the promoter of the 
miR-17-92 cluster was responsive to the E2F1-3 
transcriptional factors. This suggests that there is an auto-
regulatory mechanism in which E2F1-3 gene expression is 
controlled by miR-20a, while the miRNA expression itself is 
modulated by E2F1-3 at the transcriptional level (Fig. 3b) 
[132]. The miR-17-92 cluster is located on human 
chromosome 13q31. It has been shown that this region is 
associated with several types of lymphoma and solid tumors 
[133]; however, individual miRNAs could not accelerate 
tumor formation. The miR-17-92 cluster from polycistron 
suppresses cell death and extensive apoptosis and promotes 
high proliferation of cells. These results suggest that 
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miRNAs in the cluster or a mutation in the MYC protein. 
The genomic miRNA genes could regulate cell cycle. 
EPIGENETIC AND APOPTOSIS-RELATED miRNAs 
  The miR-21 gene was found to be upregulated in breast 
cnacer [135] and glioblastomas [135]. When expression of 
miR-21 was inhibited in glioblastomas, caspases were 
activated and an apoptotic pathway was enhanced [135]. 
Therefore, miR-21 may be an anti-apoptotic factor in human 
glioblastoma cells as well as a metastasis-related factor as 
mentioned above. 
 let-7 miRNA was reduced in lung cancer [136]. Although 
let-7 down-regulates RAS and MYC by targeting their 
mRNAs [137, 138], RAS and MYC over expression have 
been implicated in lung cancer. Therefore, it is suggested 
that regulation of let-7 levels may be a key to oncogenesis in 
human lung tissue. However, there is also evidence to the 
contrary. In some lung and colon cancers, let-7 was over 
expressed [139]. While some miRNA promoter regions 
contain putative p53 tumor suppressor (TP53) consensus 
sites, it is well known that the loss of p53 induces 
oncogenesis. The expression levels of let-7g, miR-181b and 
miR-200c were elevated in p53-deleted colon cancer [139]. 
The human let-7a-3 gene on chromosome 22q13.31 was 
associated with a CpG island, and elevated expression of let-
7a-3 in a human lung cancer resulted in enhanced tumor 
phenotypes and oncogenic changes [140]. Although human 
cancer cells are partly characterized by chromosomal 
changes in genomic DNA methylation compared with 
nonmalignant cells, Saito et al. recently treated cancer cells 
with a DNA methyltransferase inhibitor, 5-aza-2’-
deoxycytidine (DAC), and showed that miR-127 was 
affected by DNA hypermethylation [141]. These results 
suggest that miRNA may be partially responsible for 
epigenetic gene reactivation in tumor cells. 
ONCOMIR IN OTHER CANCERS 
  Evaluation of breast cancer tissue using an miRNA 
microarray showed that miR-125b, miR-145, miR-21 and 
miR-155 were significantly suppressed in cancer tissues 
[134]. In the case of Burkitt’s lymphoma, the expression of 
miR-155 increases [142, 143]. BIC, a proto-oncogene, is 
known to be activated by retroviral provirus insertion in 
certain human B cell lymphomas as well as several other 
cancers; however, the molecular basis of BIC-related cancer 
is unknown. Recently it was reported that the miR-155 gene 
locates in the region of the BIC gene (See Fig. 3b) and miR-
155 is thought to be responsible for the oncogenic activity of 
BIC via c-myc oncogene activation [142, 144]. Further, miR-
155 suppressed TP53-induced nuclear protein 1 (TP53INP1) 
expression and indirectly inhibited TP53 activity in 
pancreatic tumor (Table 1) [145]. 
 Although  Salter  et al. found that the miRNA profiles of 
normal and breast or lymphatic cancer tissues were 
significantly different, it has also been observed that miRNA 
expression pattern correlates with cancer stage, and the 
proliferation index is used for diagnosis as well as the 
prediction of chemotherapeutic response [146]. Further, 
miR-196a2 SNPs (rs11614913C/T) were related to survival 
of individuals with non-small cell lung cancer [147]. In 
addition, oncoviral integration stimulates miRNA expression 
at the integraiton site, and upregulation of oncogenic miRNA 
initiates tumorigenesis. Thus, it is suggested that 
combinational information of the resident miRNA genes, 
partially virally oncogenic miRNA genes, play an important 
role in tumorigenesis. 
MECHANISMS OF TUMORIGENESIS BY VIRAL 
miRNAs 
  miRNA may also be the master regulator of 
tumorigenesis. In the case of the human genome, miRNAs 
are usually transcribed from the intergenic non-coding 
region, either from introns or, less frequently from exons of 
the protein coding region. The intergenic non-coding region 
is corresponding to approximate 98% of genomic 
information, including retrotransposable elements (TEs) such 
as long interspersed elements (LINEs), short interspersed 
elements (SINEs), Retrotransposons and transposons. 
  Transposons have been discovered by McClintock 
approximately 50 years ago [148], TEs have been found in 
46.2% of the human genome, 34.2% of canine, 38.7% of 
murine, and 9.4% of avian genomes [149]. TEs are divided 
into class I and II. Class I elements are retroelements 
including retrotransposon, LINEs, and SINEs. The LTR 
retrotransposon is closely related to retroviruses, such as 
HIV-1, human RTL1/MART1, human endogenous 
retrovirus-K (HERV-K), Drosophila gypsy and Copia. Class 
II elements include DNA transposons. The Activator-
Dissociation (Ac-Ds) family in maize, Tam in Antirrhinum, 
the  P element in Drosophila, and the Tc1 element in C. 
elegans are well known. The recent discovered miniature 
inverted-repeat TE (MITE) has some properties of both class 
I and II elements. MITEs have been reported in plants, 
humans,  Xenopus, the yellow fever mosquito and Aedes 
aegypti [150]. DNA hypomethylation is linked to activation 
of these TEs, L1 or Alu and tumor metastasis [151]. The 
activation of TE allows for them to be transcribed and 
translocated to other genomic alleles, and for them to induce 
genomic aberrance. There is a relation between 
hypomethylation of TEs in neuroendocrine tumor and lymph 
node metastasis [152]. 
  Dobzhansky, who had a very special interest in gene 
mutation, famously said that nothing about TEs makes sense 
except in the light of evolution. But at the same time, he 
realized that a major piece of the mutation puzzle was still 
missing [153]. It is likely that the missing piece is miRNAs. 
Both type I and II TEs have hairpin structures, and the stem 
looping produces miRNAs. Further, genetic research on 
viroids has revealed that TEs are suppressed by RNA 
silencing [154]. The Tc1 can be suppressed in an RNAi-
dependent manner, and retrotransposons of S. pombe have 
also been silenced via  the RNAi pathway. The murine 
endogenous retrovirus-L (MuERV-L) and intracisternal A 
particle (IPA) retrotransposons have been silenced by Dicer 
expression [155]. From experiments on Dicer knockout (KO) 
human cells, L1 has been reported to be expressed [156]. 
  Interestingly, miRNAs have been emerged from TEs. 
The  retrotransposon-like gene 1 ( RTL1/MART1) 
(approximate 1.3 kb, 5 exon and 4 intron) in the 
DLK1/MEG3-DIO3 imprinted domain (14q32) of the human 
genome includes at least five miRNAs (Fig. 1b) [157, 158]. 
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annotated; three genes, DLK1, RTL1 and DIO3, are paternal, 
and four genes, MEG3, anti-RTL1,  MEG8 and MIRG are 
maternal. The paternally-expressed genes encode protein, but 
the maternally expressed genes represent non-coding RNA. 
Imprinting genes that implicate cell growth are often shown 
to aberrantly express in cancer [159, 160]. The miRNAs are 
transcribed only from the maternal chromosome in the 
mouse model, as are miR-127 and miR-136. RT-PCR 
showed that miR-136 is generated from a larger hot 
transcript in the anti-RTL gene, while miR-127 was only 
detected by northern blotting [161]. The generation of miR-
136 was determined but miR-127 usually could not be 
detected. 
  In the embryo brain or in the placenta, imprinting miR-
127 and RTL1 are co-expressed, suggesting that miR-127 
can maternally regulate TE itself. Further, DIRS-1 and 
Skipper retrotransposons of the social amoeba encode 
miRNAs, suggesting that miRNAs in TE may generally 
regulate TE [162]. Genome-wide research for miRNAs in 
human cells failed to uncover miR-127 function for the brain 
and the placenta, therefore, the meaning of above results has 
not yet been understood at all. In 2005, Smalheiser and 
Torvik have examined with the RepeatMasker algorithm for 
prediction of pre-miRNA and showed that the miRNA 
precursors of several highly conserved miRNAs involved 
sequences of TEs [163]. Similar to miR-N367 (or other 6 
miRNAs, TAR-3P, TAR-5P, #1, #4, #5, and H1) derived 
from HIV-1 3’-LTR (See Fig. 1b), LINE-2 miRNAs, miR-
95 and miR-151 were mapped in the 3’ end of the LINE-2 
sequence [163], and it is possible that both miRNAs target 
LINE-2-derived mRNA transcripts. Thus, we speculate that 
miRNAs might be hidden in TEs like oncoviruses in the 
chromosomal domain, and that the oncovirus-derived 
miRNAs might control the TEs themselves, while viral 
miRNAs might simultaneously have ability to regulate the 
expression of other cellular transcripts, such as those 
involved in tumorigenesis. This idea has involved into the 
RNA wave beyond the innate immune system. 
  As the proof of above speculation, murine radiation 
leukemia virus (RadLV) integration into the Kis2 locus gave 
rise to overexpression of ncRNA, which contains an miRNA 
cluster that includes miR-106a, -18b, -19b-2, -20b, -92-2 and 
-363. The overexpression of these miRNAs by oncoviral 
integration showed the oncogenic potential to murine NIH-
3T3 cells [164]. The murine mir-106-363 cluster is 
homologous to the above mentioned miR-17-92 cluster in 
humans. 
  At the integration site of the Friend murine leukemia 
virus (F-MuLV), the Fli-3 locus encodes the miR-17-92 
cluster. Induction of the miR-17-92 expression enhances 
erythroblast transformation by F-MuLV integration [165]. 
Further, the Pvt1 locus in murine encodes miR-1204, -1205, 
-1206, -1207-5p, -1207-3p and -1208. Except for miR-1206, 
all of these miRNAs have been expressed in T lymphocytes 
[166]. Although multiple myeloma cases without 
translocation of immunoglobulin gene have been observed, 
oncovirus integration into the Pvt1 locus has been shown to 
induce T lymphoma, and alteration of miRNA expression 
caused upregulation of 400kb downstream of the myc gene 
expression. However, there is no explanation for why 
integration of oncovirus without an oncogene induces 
alteration of miRNA expression. Further, no association has 
been detected between xenotropic murine leukemia virus-
related virus (XMRV) interaction sites and proto-oncogene, 
tumor suppressor gene, and miRNA gene which have been 
implicated in human prostate cancers [167]. Since 
speculative viral miRNAs were documented in human T-cell 
leukemia (lymphotropic) virus-1 (HLTV-1) oncogenesis 
[168], these pathogenic RNAs may involve miRNAs. This 
can be predicted in silico. In fact, HIV-1 provirus is known 
to express MIRH1 at certain state of infection T lymphocyte 
as mentioned above. Including the viroid case, 
retrotransposons or endogenous retroviruses as proviruses 
would encode miRNAs as hidden miRNAs and the viral 
miRNA could target miRNA itself, the miRNA cluster of its 
integration site, the actual oncogenes, and/or the tumor 
suppressor genes. 
CONCLUSIONS 
  The RNA wave consists of four concepts: 1) infection 
induces miRNA production in the virus and/or host; 2) the 
induced miRNAs have MGE-like mobility; 3) the mobile 
miRNAs can self-proliferate; and 4) cells contain both 
resident and genomic miRNAs. Based on those four 
concepts, it is possible that miRNA cannot only mediate 
RNA silencing to control expression MGEs, but also that 
miRNA may be necessary to incorporate MGEs into the 
genome for evolution. Therefore, the miRNA gene has both 
mobile and functional genetic elements. Although profiles of 
expression of oncomir and/or tumor suppressor miRNAs 
have shown that aberrant expression of the genomic miRNA 
results in tumorigenesis, which substances change miRNA 
expression and why have not been ascertained. Therefore, 
the primary cause of altered miRNA expression in cancer 
cells is still unaccounted for. 
  One of environmental factors based on the two-hit 
hypothesis could be oncovirus as the MGE inserting into the 
integration loci, which encodes the miRNA genes; as a 
result, the insertion would alter the expression profile of the 
miRNA genes. This process has been shown to induce 
tumorigenesis; however, if pathogenic resident miRNA were 
picked up into an oncovirus as a tag and then ectopically 
integrated into the chromosome, the integrated miRNA gene 
as would act like foreign DNA and could result in imposition 
of epigenetic regulation, like imprinting, that may 
occasionally induce tumorigenesis in host cells. 
Nevertheless, the pathogenic viral miRNA and activated 
endogenous retrotransposon miRNA should translocate and 
duplicate the miRNA genes within the host chromosome. 
Tumorigenesis may result from a “tsunami” of emerging 
oncogenic viral RNA codes in the oncoviral genome. 
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ABBREVIATIONS 
AATF  =  Apoptosis antagonizing transcription factor 
abl  =  Abelson mouse leukemia 
Ac-Ds =  Activator-Dissociation 
Ago =  Argonaute Prototype Onco-miRNA Integration  The Open Virology Journal, 2009, Volume 3    47 
AIDS  =  Human acquired immunodeficiency  
     syndrome 
-gal =  -galactosidase 
CDK4/6  =  Cyclin kinase 4/6 
Chp =  Chromodomain  protein 
CLL =  Chronic  lymphocytic  leukemia 
c-onc =  Cellular  oncogene 
DGCR8  =  DiGeorge syndrome critical region gene 8 
dsDNA =  Double-stranded  DNA 
dsRNA =  Double-stranded  RNA 
EBV =  Epstein-Barr  virus 
EMT =  Epithelial-mesenchymal  transition 
ES =  Embryonic  stem 
EXP5 =  Exportin  5 
F-MuLV  =  Friend murine leukemia virus 
GFP  =  Green fluorescent protein 
HERV-K =  Human  endogenous  retrovirus-K 
HIV-1  =  Human immunodeficiency virus type 1 
H3K9  =  Methylation of the lysine residue at position  
     9 of histone H3 
HLTV-1  =  Human T-cell leukemia (lymphotropic)   
     virus-1 
HP1  =  Heterochromatin protein 1 
IG =  Immunoglobulin 
IPA  =  Intracisternal A particle 
KO =  Knockout 
KS =  Kaposi’s  sarcoma 
KSHV =  Kaposi  sarcoma-associated  herpesvirus 
LANA  =  Latency-associated nuclear antigen 
LINE =  Long  interspersed  element 
LTR  =  Long terminal repeat 
MET =  Mesenchymal-epithelial  transition 
MGE =  Mobile  genetic  element 
miRISC  =  miRNA-induced silencing complex 
miRNA =  microRNA 
MITE =  Miniature  inverted-repeat  TE 
MLV =  Murine  leukemia  virus 
mRNA =  Messenger  RNA 
myc =  Avian  myelocytomatosis 
NHL =  Non-Hodgkin’s  lymphoma 
nts =  Nucleotides 
oncomir =  Oncogenic  miRNA 
PACT  = Protein activator of protein kinase activated  
     by dsRNA 
Par-4 =  Prostate  apoptosis-4 
PAZ =  Piwi/Argonaute/Zwille 
P-body =  Processing  body 
PCNSL  =  Primary central nervous system lymphoma 
pre-miRNA = Precursor  miRNA 
Ph =  Philadelphia 
pri-miRNA = Primary  miRNA 
Pol =  RNA  polymerase 
PVT =  Plasmacytoma  variant  translocation 
QTL =  Quantitative  trait  loci 
RB =  Retinoblastoma  (protein) 
RDRC =  RdRP  complex 
RdRP =  RNA-directed  RNA  polymerase 
RISC  =  RNA-induced silencing complex 
RITS  =  RNA-induced transcriptional complex 
RNAi =  RNA  interference 
SINE =  Short  interspersed  element 
siRNA =  Short  interfering  RNA 
TE =  Retrotransposable  element 
TGS =  Transcriptional  silencing 
TP53INP1  =  Tumor protein 53-induced nuclear protein 1 
TRBP  =  Trans-activator RNA (TAR)-binding protein 
UTR =  Untranslated  region 
v-onc =  Viral  oncogene 
XMRV  = Xenotropic murine leukemia virus-related   
     virus 
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